Please Scroll Down to See Forums Below 
TheRide
New member
Poor fellas... their stock is taking a beating...
Support you local AAS producer, use Schering
Schering (SHR) is far too expensive without its Bonefos drug, which the company said the Food and Drug Administration has requested more information on, according to Dr. Martin Possienke, an analyst for German broker Equinet. "As everybody expected straightforward approval today, the approvable letter is more than disappointing. How negative this will be for Schering depends on the kind of additional data the FDA wants to see. It they wanted additional clinical data, it would be catastrophic for Schering as most likely they can not provide supporting data before 2007," the broker said. Schering shares were off 3.9 percent.
Support you local AAS producer, use Schering
Schering (SHR) is far too expensive without its Bonefos drug, which the company said the Food and Drug Administration has requested more information on, according to Dr. Martin Possienke, an analyst for German broker Equinet. "As everybody expected straightforward approval today, the approvable letter is more than disappointing. How negative this will be for Schering depends on the kind of additional data the FDA wants to see. It they wanted additional clinical data, it would be catastrophic for Schering as most likely they can not provide supporting data before 2007," the broker said. Schering shares were off 3.9 percent.
